Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2026 vs. Q1 2026
How the institutions holding Aligos Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 35 | 31 | −4 |
| Shares | 2.78M | 2.29M | −482.6K (−17.4%) |
| Value | $20.6M | $13.2M | −$7.39M (−35.8%) |
New holders (5)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 32,402 | $187.0K | 0.00% |
| Dimensional Fund Advisors LP | 21,044 | $121.4K | 0.00% |
| Trexquant Investment LP | 12,339 | $71.2K | 0.00% |
| Citigroup Inc | 1,808 | $10.4K | 0.00% |
| FMR LLC | 10 | $58 | 0.00% |
Sold out (9)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Bank of America Corp | 229,754 | $1.71M |
| SummitTX Capital, L.P. | 148,799 | $1.11M |
| Citadel Advisors LLC | 54,311 | $403.5K |
| LPL Financial LLC | 51,500 | $382.6K |
| Two Sigma Investments, LP | 23,093 | $171.6K |
| XTX Topco Ltd | 14,196 | $105.5K |
| Quadrature Capital Ltd | 10,822 | $80.4K |
| Vanguard Global Advisers, LLC | 936 | $6.95K |
| Fortitude Family Office, LLC | 68 | $505 |